Xcout Intel
Healome
Healome Therapeutics Ltd is an eye care and ophthalmology therapeutics company founded in 2021 and headquartered in Birmingham, United Kingdom. The company develops safer and more effective ocular drug delivery treatments for vision-threatening ocular surface diseases.
Subscribe to see Healome’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Healome at a glance
Healome is a biotech company headquartered in United Kingdom. Its most recent funding round, Seed, raised $2.7M in July 2026. Xcout tracks 1 named person at Healome, including Richard Williams (Chief Executive).
Healome leadership
- Richard WilliamsChief Executive
Healome funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $2.7M | 5 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Healome competitors
A few of Healome's closest competitors — see the full list of competitors and alternatives →
MCAL Therapeutics Inc. is a biotechnology company developing synthetic, rabbit-inspired lipid eye drops and extended-release drug delivery platforms. Its lead candidate, MCAL-201, is designed to treat evaporative dry eye disease by restoring the tear film's protective lipid barrier.
Alkeus Pharmaceuticals, Inc. is a late-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing treatments that preserve the sight of individuals impacted by severe eye diseases.
Eyevensys is a biotechnology company developing non-viral gene therapies for ophthalmic diseases. Its platform uses electro-transfection of the eye’s ciliary muscle to enable sustained local production of therapeutic proteins for retinal and other ocular conditions.
Alterome Therapeutics, Inc. is a clinical-stage precision oncology company headquartered in San Diego, California, founded in 2021. The privately held biotech firm focuses on developing targeted therapies to address genomically defined cancer drivers and intractable oncological targets.
Tarsier Pharma Ltd. is a late clinical-stage pharmaceutical company that develops bio-inspired medical solutions for autoimmune and inflammatory ocular diseases. The company utilizes a proprietary molecule-derived technology platform to target conditions such as non-infectious uveitis and uveitic glaucoma through eye drops and intravitreal injections.
Aperta Biosciences is a biopharmaceutical company that develops novel therapeutics for ocular surface diseases, including blepharitis, ocular rosacea, meibomian gland dysfunction, and dry eye disease. The company's lead candidate, APT-001, is an ophthalmic suspension designed to treat the underlying cause of blepharitis by eradicating ocular Demodex infestations.
Get Healome's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Healome in Xcout Intel
- 1 named person with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access